retatrutide phase 2 nejm 2023 obesity trial jastreboff Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide vs Semaglutide: Triple vs

doi: 10.1016/j.arth.2023.12.023

Generics to dramatically cut cost: experts Novo Nordisk the company behind blockbuster diabetes and weight-loss drugs Ozempic and Wegovy had for years held a patent on semaglutide, the active ingredient in those drugs that triggers the release of insulin and is used to treat diabetes and to aid weight loss

Aging rewires metabolism, immunity, and gene regulation across organs, steadily sapping strength, cognition, and resilience

Libido is a brain-driven process powered by dopamine signaling

If you want the deeper science on how the two work together, see our primer on prebiotics, probiotics, and synbiotics

Glucagonlike peptide1: actions and influence on pancreatic hormone function